Patient-Reported Benefits of Acoramidis Across Genotypes in Transthyretin Amyloid Cardiomyopathy: KCCQ and EQ-5D-5L Outcomes From ATTRibute-CM.

IF 9.9 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiac Failure Pub Date : 2026-10-11 DOI:10.1016/j.cardfail.2026.09.016

Emer Joyce, Ahmad Masri, Laura Obici, Peter VAN-DER-Meer, Jan M Griffin, Keyur Shah, Zubair Shah, Tracy Bergemann, Gillian Murtagh, Heather Falvey, Jean-François Tamby, Margot K Davis, Francesco Cappelli, Steen Hvitfeldt Poulsen, Joshua D Mitchell, Mazen Hanna, Brett W Sperry, Nitasha Sarswat

引用次数: 0

查看原文本刊更多论文

Acoramidis在转甲状腺素淀粉样心肌病中跨基因型患者报告的益处：来自属性- cm的KCCQ和EQ-5D-5L结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiac Failure 医学-心血管系统

CiteScore

7.80

自引率

8.30%

发文量

653

审稿时长

21 days

期刊介绍： Journal of Cardiac Failure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure - pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.